Indoco Remedies Ltd. reported mixed financial results for Q3 FY26, with consolidated revenue growing 7% year-on-year to ₹4,454 million from ₹4,106 million in Q3 FY25, driven primarily by Export Formulations and API business segments. However, consolidated net loss widened to ₹295 million from ₹284 million in the corresponding period last year, impacted by exceptional items totaling ₹615 million including New Labour Codes implementation. On a standalone basis, revenue from operations stood at ₹3,896 million compared to ₹3,649 million in Q3 FY25, while standalone net loss increased to ₹200 million from ₹102 million in the previous year. The company's earnings per share on a consolidated basis stood at ₹(3.20) compared to ₹(3.08) in Q3 FY25, reflecting deteriorating profitability despite revenue growth.
The company demonstrated strong operational performance with consolidated EBITDA rising 29% to ₹259 million from ₹201 million in Q3 FY25, registering significant improvement in operational efficiency. EBITDA margins expanded substantially from previous quarters, indicating enhanced cost management and business optimization efforts. Managing Director Ms. Aditi Panandikar attributed the revenue growth primarily to the Export Formulations business and API business segments, with the company's geographic revenue split showing India contributing ₹2,954 million and international markets ₹1,389 million to consolidated operations. This strong EBITDA performance, combined with the company's global presence spanning multiple manufacturing facilities and regulatory approvals from USFDA and UK-MHRA, positions it well for continued growth across domestic and international markets.
The company's financial results include exceptional items totaling ₹615 million on a consolidated basis, primarily comprising consideration received of ₹253 million for trademark licensing rights, loss of ₹213 million on sale and leaseback of non-current assets, and ₹708 million impact from implementation of New Labour Codes effective November 21, 2025. The statutory auditors M/s. Gokhale & Sathe have issued an unmodified opinion on the unaudited financial results. Additionally, Indoco Remedies has officially reported a GST inspection conducted by Maharashtra State GST Department on February 2, 2026, under Section 67 of CGST and SGST Acts. The inspection involves verification of books of accounts from 2020-2021 to present, with the company providing full cooperation and maintaining compliance with SEBI disclosure requirements.
The most critical development remains the declaration of 'material uncertainty that may cast significant doubt on their ability to continue as going concerns' for subsidiaries FPP Holding LLC and Warren Remedies Private Limited. According to the company's disclosure, these entities report negative net worths of ₹34.28 crore and ₹59 crore respectively. Management's statement that impairment testing concluded no provision is necessary 'at this stage' is likely to draw intense scrutiny from analysts and investors. The going concern uncertainty poses a threat to the group's consolidated financial stability, its ability to access credit, and overall operational continuity.
Despite the mixed financial performance, shares of Indoco Remedies surged 11.53% on February 3, 2026 to close at ₹236.00, though this represents a 32.20% decline from its 52-week high of ₹348.10. The stock's current valuation appears disconnected from fundamentals, with the company trading at a price-to-book value of 1.99 times and enterprise value-to-EBITDA multiple of 40.81 times. Analysts have assigned a 'Risky' valuation grade and Mojo Score of just 17 out of 100, reflecting multiple red flags including negative returns on capital, mounting leverage, and uncertain turnaround prospects. The stock's beta of 1.35 indicates it is 35% more volatile than the broader market, with negative alpha across all timeframes highlighting persistent underperformance against sector benchmarks.
